Inhibition of pancreatic carcinoma growth by adenovirus-mediated human interleukin-24 expression in animal model

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 4, 2008, Pages 425-434

  Pan, Xinting ^a   Sheng, Weihua ^a   Zhu, Qingyun ^a   Xie, Yufeng ^a   Ye, Zhenmin ^b   Xiang, Jim ^b   Li, Dechun ^a   Yang, Jicheng ^a  

^a SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adenovirus; Angiogenesis; IL 24 gene therapy; Pancreatic carcinoma

Indexed keywords

ADENOVIRUS VECTOR; BETA INTERFERON; CD34 ANTIGEN; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 24; MEZEREIN; PROTEIN BCL 2; PROTEIN KINASE; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CYTOTOXICITY; GENE CONSTRUCT; GENE THERAPY; GROWTH INHIBITION; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD34; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INTERLEUKINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51349141767     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0461     Document Type: Article

References (42)

1. Yeh JJ, Der CJ. Targeting signal transduction in pancreatic cancer treatment. Exp Opin Ther Targ 2007;11:673.
2. Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: An institutional experience. Ann Surg 2007;245:273.
3. Kasuya H, Nishiyama Y, Nomoto S, et al. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther 2007;14:533.
4. Qian C, Drozdzik M, Caselmann WH, et al. The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol 2000;32:344.
5. Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther 2007;14:488.
6. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: Hard lessons and new courses. Gene Ther 2000;7:2.
7. Lebedeva IV, Sarkar D, Su ZZ. Molecular target-based therapy of pancreatic cancer. Cancer Res 2006;66:2403.
8. Runnebaum IB. Basics of cancer gene therapy. Anticancer Res 1997;17:2887.
9. Saito Y, Miyahara R, Gopalan B, et al. Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated-7(MDA-7)/interleukin-24 (IL-24) gene. Cancer Gene Ther 2005;12:238.
10. Miyahara R, Banerjee S, Kawano K, et al. Melanoma differentiation- associated gene-7 (MDA-7)/interleukin (IL)-24 induces anticancer immunity in a syngeneic murine model. Cancer Gene Ther 2006;13:753.
11. Jiang H, Lin JJ, Su ZZ, et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, MDA-7, modulated during human melanoma differentiation, growth, and progression. Oncogene 1995;11:2477.
12. Chada S, Sutton RB, Ekmekcioglu S, et al. MDA-7/IL-24 is a unique cytokine - tumor suppressor in the IL-10 family. Int Immunopharmacol 2004;4:649.
13. Sauane M, Gopalkrishnan RV, Sarkar D, et al. MDA-7/IL-24: Novel cancer growth-suppressing and apoptosis-inducing cytokine. Cytokine Growth Fact Rev 2003;14:35.
14. Onn A, Herbst RS. Angiogenesis and lung cancer: Implications for prognosis and treatment. Lancet Oncol 2007;8:460.
15. Kindler HL, Friberg G, Singh DA. Phase trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033.
16. Miller KD, Sledge GW, Burstein HJ. Angiogenesis inhibition in the treatment of breast cancer: A review of studies presented at the 2006 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol 2007;5:1.
17. Wu HP, Feng GS, Liang HM, et al. Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. World J Gastroenterol 2004;10:813.
18. Bergers G, Javaherian K, Lo KM, et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808.
19. Huang EY, Madireddi MT, Gopalkrishnan RV, et al. Genomic structure, chromosomal localization, and expression profile of a novel melanoma differentiation associated (MDA-7) gene with cancer specific growth-suppressing and apoptosis-inducing properties. Oncogene 2001;20:7051.
20. Zheng M, Bocangel D, Doneske B, et al. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother 2007;56:205.
21. Wang M, Tan Z, Zhang R, et al. Interleukin-24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem 2002;277:7341.
22. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, et al. Downregulated melanoma differentiation associated gene (MDA-7) expression in human melanomas. Int J Cancer 2001;94:54.
23. Cao XX, Mohuiddin I, Chada S, et al. Adenoviral transfer of MDA-7 leads to BAX upregulation and apoptosis in mesothelioma cells and is abrogated by overexpression of BCL-XL. Mol Med 2002;8:869.
24. Pataer A, Vorburger SA, Barber GN, et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (MDA7) induces apoptosis of lung cancer cells via upregulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 2002;62:2239.
25. Mhashilkar AM, Stewart AL, Sieger K, et al. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther 2003;8:207.
26. Yacoub A, Mitchell C, Brannon J, et al. MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. Mol Cancer Ther 2003;2:623.
27. Sieger KA, Mhashilkar AM, Stewart A, et al. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther 2004;9:355.
28. Sarkar D, Su ZZ, Lebedeva IV, et al. MDA-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 2002;99:10054.
29. Sangro B, Herraiz M, Prieto J. Gene therapy of neoplastic liver diseases. Int J Biochem Cell Biol 2003;35:135.
30. Sarkar D, Su ZZ, Lebedeva IV, et al. MDA-7(IL-24): Signaling and functional roles. Biotechniques 2002;33:S30.
31. Mhashilkar AM, Schrock RD, Hindi M, et al. Melanoma differentiation associated gene-7 (MDA-7): A novel antitumor gene for cancer gene therapy. Mol Med 2001;7:271.
32. Mahasreshti PJ, Kataram M, Wu H, et al. Ovarian-cancer-targeted adenoviral-mediated MDA-7/IL-24 gene therapy. Gynecol Oncol 2006;100:521.
33. Yang J, Zhang W, Liu K, et al. Expression, purification, and characterization of recombinant human interleukin-24 in Escherichia coli. Prot Expr Purif 2007;53:339.
34. Gopalan B, Shanker M, Chada S, et al. MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo. Mol Cancer 2007;6:11.
35. Gupta P, Su ZZ, Lebedeva IV, et al. MDA-7/IL-24: Multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther 2006;111:596.
36. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323.
37. Zhou Z, Zhou RR, Guan H, et al. E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Mol Cancer Ther 2003;2:1313.
38. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000;5:37.
39. Vieira SC, Silva BB, Pinto GA, et al. CD34 as a marker for evaluating angiogenesis in cervical cancer. Pathol Res Pract 2005;201:313.
40. Semenza GL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003;54:17.
41. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004;41:864.
42. Stabenow E, Tavares MR, Ab'Saber AM, et al. Angiogenesis as an indicator of metastatic potential in papillary thyroid carcinoma. Clinics 2005;60:233.